Risk of ocular adverse events with aromatase inhibitors
CONCLUSION: Disproportionality analysis revealed an increased risk of ocular AEs with each of the AIs. This study calls for clinicians, especially oncologists and ophthalmologists, to be vigilant in patients who are on AI therapy, allowing them to provide prompt interventions to mitigate further ocular morbidities.PMID:37931898 | DOI:10.1016/j.jcjo.2023.10.013
Source: Cancer Control - Category: Cancer & Oncology Authors: Zhao Xun Feng Aswen Sriranganathan Cody Lo Victoria Liu David Maberley Mahyar Etminan Source Type: research
More News: Arimidex | Blepharitis | Brain | Breast Cancer | Cancer | Cancer & Oncology | Databases & Libraries | Herceptin | Neurology | Opthalmology | Study | Vitamin A